The standard case for the fund is to invest in rounds with more than 10 partakers. Despite the LVP Life Science Ventures, startups are often financed by PathoCapital, OUP (Osage University Partners), Northwestern University. The meaningful sponsors for the fund in investment in the same round are Rock Springs Capital, PathoCapital, Partner Fund Management.
The top activity for fund was in 2017. The higher amount of exits for fund were in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 deals per year.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical. Among the most popular portfolio startups of the fund, we may highlight Aptinyx.
Related Funds
| Fund Name | Location |
| Alerion Ventures | Charleston, South Carolina, United States |
| Century Oak Capital | Liechtenstein, Oberland, Vaduz |
| Coalition for Epidemic Preparedness Innovations | District of Columbia, United States, Washington |
| DSCN Capital | Florida, Miami Beach, United States |
| Forticom | Latvia, Riga, Vidzeme |
| Gansu Gangtai Holding (Group) | China, Shanghai |
| Global Ventures | Dubai, United Arab Emirates |
| Grand Flight Investment | China, Shanghai |
| Hudson Valley Startup Fund | Kingston, New York, United States |
| ICICI Investment Management | India, Maharashtra, Mumbai |
| Jingsheng Jiacheng Investment | - |
| Larsen & Toubro Limited | India, Maharashtra, Mumbai |
| Lewis & Clark Ventures | Missouri, St Louis, United States |
| Maloekoe Ventures | Indonesia, Jakarta, Jakarta Raya |
| Rothschild & Cie | - |
| SE Agoura Investment | California, Los Angeles, United States |
| SEICHO | Japan, Tokyo |
| Toyota Financial Services | California, Torrance, United States |
| Trigyn Technologies | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Aptinyx | $70M | 18 Dec 2017 | Illinois, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Aptinyx | $70M | 18 Dec 2017 | Illinois, United States |
